Targeted Oncology

, Volume 6, Issue 2, pp 69–94

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors

  • Yesid Alvarado
  • Monica M. Mita
  • Sushma Vemulapalli
  • Devalingam Mahalingam
  • Alain C. Mita
Review

DOI: 10.1007/s11523-011-0178-5

Cite this article as:
Alvarado, Y., Mita, M.M., Vemulapalli, S. et al. Targ Oncol (2011) 6: 69. doi:10.1007/s11523-011-0178-5

Abstract

The phosphatidylinositol 3-kinase (PI3K)–Akt–mammalian target of rapamycin (mTOR) pathway is vital for cell metabolism, growth, and proliferation. mTOR is frequently upregulated in many tumor types and hence has become an important target in cancer treatment. Sirolimus and its derivatives (rapalogs) interact with the intracellular receptor FK506 binding protein 12 (FKBP12), forming a complex with high affinity for mTOR and thus disrupting its activity. Rapalogs are being evaluated extensively in cancer patients with different formulations and schedules. Significant clinical activity has led to their approval for the treatment of kidney cancer, mantle cell lymphoma, and subependymal giant cell astrocytoma; however, despite increasing knowledge about cancer cell biology, their activity in other malignancies is unclear. Further research is needed to identify optimal dosage, administration and targeted combination as well as the subset of patients likely to respond to mTOR/PI3K inhibition. This review focuses on a discussion of the pathway, its implications in cancer biology and results of clinical trials of rapalogs alone or in combination, organizing them by common malignancy type.

Keywords

Mammalian Target of Rapamycin mTOR mTOR inhibitors Rapalogs 

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Yesid Alvarado
    • 1
  • Monica M. Mita
    • 1
  • Sushma Vemulapalli
    • 1
  • Devalingam Mahalingam
    • 1
  • Alain C. Mita
    • 1
  1. 1.Department of Hematology Oncology, Institute for Drug developmentThe University of Texas Health Science Center San AntonioSan AntonioUSA